← Back to Clinical Trials
Recruiting NCT06308172

NCT06308172 Impact of Single- Versus Double-layer Hysterotomy Closure on Cesarean Niche Development: a Randomized Controlled Trial

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06308172
Status Recruiting
Phase
Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Condition Cesarean Section; Dehiscence
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2021-12-01
Primary Completion 2024-12-01

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Hysterotomy closure

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2021-12-01 with a primary completion date of 2024-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this randomized monocentric study is to assess potential variations in the incidence and severity of isthmocele morbidity among women undergoing cesarean section with either single or double-layer closure of the hysterotomy. Our primary outcome aims to investigate whether there is a reduction in the median duration of intermenstrual spotting in patients belonging to the two respective closure groups

Eligibility Criteria

Inclusion Criteria: * nulliparous * singleton * age 18-45 * spontaneous pregnancy or autologous assisted fertilization * gestational age 38-40 weeks * elective C-section * informed consent Exclusion Criteria: * coagulopathy * autoimmune diseases * gestational diabetes * anticoagulant therapy * immunosuppressive therapy * endometriosis * uterine fibromatosis * spontaneous labour * connective tissue diseases

Contact & Investigator

Central Contact

Giuseppe Perugino, MD

✉ giuseppe.perugino@policlinico.mi.it

📞 3383030553

Principal Investigator

Giuseppe Perugino, MD

PRINCIPAL INVESTIGATOR

Ospedale Policlinico Maggiore Ca' Granda Milano

Frequently Asked Questions

Who can join the NCT06308172 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Cesarean Section; Dehiscence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06308172 currently recruiting?

Yes, NCT06308172 is actively recruiting participants. Contact the research team at giuseppe.perugino@policlinico.mi.it for enrollment information.

Where is the NCT06308172 trial being conducted?

This trial is being conducted at Milan, Italy.

Who is sponsoring the NCT06308172 clinical trial?

NCT06308172 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The principal investigator is Giuseppe Perugino, MD at Ospedale Policlinico Maggiore Ca' Granda Milano. The trial plans to enroll 150 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology